DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer ...

Biomarkers such as homologous recombination deficiency (HRD) and prostate-specific membrane antigen (PSMA) can sway treatment ...

A novel immune-based therapy shows 100% response rates in newly diagnosed multiple myeloma patients, highlighting its ...

HIF-2α inhibitors, like belzutifan, are emerging as promising second-line treatments for RCC, with ongoing trials showing ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...